Xpeng, Li Auto latest to get approval to test ‘hands-off’ driving amid slowing car market


Two leading Chinese electric vehicle (EV) makers, Xpeng and Li Auto, have been granted licences to test their level 3 (L3) autonomous driving technologies in designated urban areas, the latest sign that Beijing is encouraging wider use of advanced driver assistance systems amid a slowing automotive market.

The green light came just one day after the Ministry of Industry and Information Technology (MIIT) gave another two carmakers – Changan Automobile and BAIC – approvals to start assembling new models fitted with L3 self-driving systems.

Xpeng, backed by Volkswagen Group, would be allowed to conduct tests on certain roads in its home base of Guangzhou, while Li Auto, a Tesla challenger in mainland China, could do the same in designated areas in Beijing, where it is headquartered, according to industry officials with knowledge of the matter.

L3 systems are considered “hands-off” under the criteria set by global standards organisation SAE International, but drivers are still required to be fully alert to ensure that they can intervene under any circumstances.

Neither Xpeng nor Li Auto would comment on this development when contacted by the South China Morning Post on Tuesday.

Electric vehicles on show at Xpeng’s headquarters in Guangzhou, in southern China’s Guangdong province, November 5, 2025. Photo: AFP
Electric vehicles on show at Xpeng’s headquarters in Guangzhou, in southern China’s Guangdong province, November 5, 2025. Photo: AFP

Deregulation to legalise L3 technology represents a leap forward in commercialising autonomous driving systems in China, the world’s largest automotive market, analysts say.

  • Related Posts

    Lean harder into Hong Kong-mainland China market ties, ‘two sessions’ delegates urge

    Hong Kong can reinforce its role as an international financial centre by deepening integration with mainland capital markets and expanding cross-border investment channels, financial industry leaders said on Thursday during…

    Continue reading
    Insilico Medicine advances Middle East push with UAE AI drug discovery deal

    Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates’ drug regulator to advance the use of its artificial intelligence tools in drug discovery across the…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *